Anlotinib for Esophageal Cancer (AFEC)
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.
Esophageal Cancer
DRUG: Anlotinib
OS, Overall Survival, From date of admission until the date of death from any cause, assessed up to 24 months
PFS, Progression Free Survival, From date of admission until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 24 months
The purpose of this study is to observe and explore the effect of single or combined treatment of arotinib on the survival and prognosis of patients with advanced esophageal cancer in the real world, and to summarize the treatment experience of a wide range of people.